Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2023

Open Access 01-12-2023 | NSCLC | Research

The use of non-steroid anti-inflammatory drugs during radical resection correlated with the outcome in non-small cell lung cancer

Authors: Renzhong Cai, Xuqiang Liao, Gao Li, Jia Xiang, Qianwen Ye, Minbiao Chen, Shouhan Feng

Published in: World Journal of Surgical Oncology | Issue 1/2023

Login to get access

Abstract

Aims

The use of non-steroid anti-inflammatory drugs (NSAIDs) is conventional in management of postoperative pain in cancer patients, and further investigations have reported that some of these drugs correlated with the outcome in cancers. However, the prognostic value of the use of NSAIDs during surgery in non-small cell lung cancer (NSCLC) patients has been less addressed.

Methods

NSCLC patients staged I–III are retrospectively enrolled, and the data of the use of NSAIDs during surgery are collected. Patients are divided into two subgroups according to the use intensity (UI) (low or high) of the NSAIDs, which was calculated by the accumulate dosage of all the NSAIDs divided by the length of hospitalization. The differences of the clinical features among these groups were checked. And the disease-free survival (DFS) and overall survival (OS) differences in these groups were compared by Kaplan–Meier analysis; risk factors for survival were validated by using a Cox proportional hazards model.

Results

The UI was significant in predicting the DFS (AUC = 0.65, 95% CI: 0.57–0.73, P = 0.001) and OS (AUC = 0.70, 95% CI: 0.59–0.81, P = 0.001). Clinical features including type of resection (P = 0.001), N stages (P < 0.001), and TNM stages (P = 0.004) were significantly different in UI low (< 74.55 mg/day) or high (≥ 74.55 mg/day) subgroups. Patients in UI-high subgroups displayed significant superior DFS (log rank = 11.46, P = 0.001) and OS (log rank = 7.63, P = 0.006) than the UI-low ones. At last, the UI was found to be an independent risk factor for DFS (HR: 0.52, 95% CI: 0.28–0.95, P = 0.034).

Conclusions

The use of NSAIDs during radical resection in NSCLC patients correlated with the outcome and patients with a relative high UI has better outcome.
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun. 2022;42(10):937–70.CrossRef
3.
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–85.PubMedPubMedCentralCrossRef
4.
O’Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23(10):1274–86.PubMedCrossRef
5.
Lv C, Fang W, Wu N, Jiao W, Xu S, Ma H, et al. Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): a multicenter, single-arm, open-label phase 2b trial. Lung Cancer. 2023;178:151–6.PubMedCrossRef
6.
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383(18):1711–23.PubMedCrossRef
7.
Bendixen M, Jørgensen OD, Kronborg C, Andersen C, Licht PB. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial. Lancet Oncol. 2016;17(6):836–44.PubMedCrossRef
8.
Yoon S, Hong WP, Joo H, Kim H, Park S, Bahk JH, et al. Long-term incidence of chronic postsurgical pain after thoracic surgery for lung cancer: a 10-year single-center retrospective study. Reg Anesth Pain Med. 2020;45(5):331–6.PubMedCrossRef
9.
Oh TK, Jeon JH, Lee JM, Kim MS, Kim JH, Cho H, et al. Investigation of opioid use and long-term oncologic outcomes for non-small cell lung cancer patients treated with surgery. PLoS One. 2017;12(7):e0181672.PubMedPubMedCentralCrossRef
10.
11.
Zhao M, Wang T, Hui Z. Aspirin overcomes cisplatin resistance in lung cancer by inhibiting cancer cell stemness. Thoracic Cancer. 2020;11(11):3117–25.PubMedPubMedCentralCrossRef
12.
Ogawa F, Amano H, Ito Y, Matsui Y, Hosono K, Kitasato H, et al. Aspirin reduces lung cancer metastasis to regional lymph nodes. Biomed Pharmacother. 2014;68(1):79–86.PubMedCrossRef
13.
Endo H, Yano M, Okumura Y, Kido H. Ibuprofen enhances the anticancer activity of cisplatin in lung cancer cells by inhibiting the heat shock protein 70. Cell Death Dis. 2014;5(1):e1027.PubMedPubMedCentralCrossRef
14.
Wang ZL, Fan ZQ, Jiang HD, Qu JM. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling. Carcinogenesis. 2013;34(3):638–46.PubMedCrossRef
15.
Liu X, Hong L, Nilsson M, Hubert SM, Wu S, Rinsurongkawong W, et al. Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Lung Cancer. 2020;149:33–40.PubMedCrossRef
16.
Aiad M, Tahir A, Fresco K, Prenatt Z, Ramos-Feliciano K, Walia J, et al. Does the combined use of aspirin and immunotherapy result in better outcomes in non-small cell lung cancer than immunotherapy alone? Cureus. 2022;14(6):e25891.PubMedPubMedCentral
17.
Gadgeel SM, Ruckdeschel JC, Heath EI, Heilbrun LK, Venkatramanamoorthy R, Wozniak A. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). J Thorac Oncol. 2007;2(4):299–305.PubMedCrossRef
18.
Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, et al. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol. 2011;29(32):4320–6.PubMedCrossRef
19.
Jiang W, Wang L, Zhang J, Shen H, Dong W, Zhang T, et al. Effects of postoperative non-steroidal anti-inflammatory drugs on long-term survival and recurrence of patients with non-small cell lung cancer. Medicine. 2018;97(39):e12442.PubMedPubMedCentralCrossRef
20.
Xu H, Zhao G, Lin J, Ye Q, Xiang J, Yan B. A combined preoperative red cell distribution width and carcinoembryonic antigen score contribute to prognosis prediction in stage I lung adenocarcinoma. World J Surg Oncol. 2023;21(1):56.PubMedPubMedCentralCrossRef
21.
Chudy-Onwugaje K, Huang WY, Su LJ, Purdue MP, Johnson CC, Wang L, et al. Aspirin, ibuprofen, and reduced risk of advanced colorectal adenoma incidence and recurrence and colorectal cancer in the PLCO Cancer Screening Trial. Cancer. 2021;127(17):3145–55.PubMedCrossRef
22.
Lim WY, Chuah KL, Eng P, Leong SS, Lim E, Lim TK, et al. Aspirin and non-aspirin non-steroidal anti-inflammatory drug use and risk of lung cancer. Lung Cancer. 2012;77(2):246–51.PubMedCrossRef
23.
McCormack VA, Hung RJ, Brenner DR, Bickeböller H, Rosenberger A, Muscat JE, et al. Aspirin and NSAID use and lung cancer risk: a pooled analysis in the International Lung Cancer Consortium (ILCCO). Cancer Causes Control. 2011;22(12):1709–20.PubMedCrossRef
24.
Ye S, Lee M, Lee D, Ha EH, Chun EM. Association of long-term use of low-dose aspirin as chemoprevention with risk of lung cancer. JAMA Netw Open. 2019;2(3):e190185.PubMedPubMedCentralCrossRef
25.
Giampieri R, Restivo A, Pusceddu V, Del Prete M, Maccaroni E, Bittoni AF, et al. The role of aspirin as antitumoral agent for heavily pretreated patients with metastatic colorectal cancer receiving capecitabine monotherapy. Clin Colorectal Cancer. 2017;16(1):38–43.PubMedCrossRef
26.
Chuang MC, Yang YH, Hsieh MJ, Lin YC, Yang TM, Chen PC, et al. The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study. BMC Cancer. 2021;21(1):1257.PubMedPubMedCentralCrossRef
27.
Kanda A, Ebihara S, Okazaki T, Yasuda H, Sasaki H. Loxoprofen sodium and survival in older people with advanced non-small cell lung cancer. J Am Geriatr Soc. 2004;52(3):471–2.PubMedCrossRef
28.
Gulyas M, Mattsson JSM, Lindgren A, Ek L, Lamberg Lundström K, Behndig A, et al. COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer. Acta Oncol. 2018;57(2):244–50.PubMedCrossRef
29.
30.
Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol. 2010;28(9):1467–72.PubMedPubMedCentralCrossRef
31.
Liao SF, Koshiol J, Huang YH, Jackson SS, Huang YH, Chan C, et al. Postdiagnosis aspirin use associated with decreased biliary tract cancer-specific mortality in a large nationwide cohort. Hepatology. 2021;74(4):1994–2006.PubMedCrossRef
32.
Walker AJ, Grainge MJ, Card TR. Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study. Br J Cancer. 2012;107(9):1602–7.PubMedPubMedCentralCrossRef
33.
Gan H, Lin L, Hu N, Yang Y, Gao Y, Pei Y, et al. Aspirin ameliorates lung cancer by targeting the miR-98/WNT1 axis. Thorac Cancer. 2019;10(4):744–50.PubMedPubMedCentralCrossRef
34.
35.
Gai C, Yu M, Li Z, Wang Y, Ding D, Zheng J, et al. Acetaminophen sensitizing erastin-induced ferroptosis via modulation of Nrf2/heme oxygenase-1 signaling pathway in non-small-cell lung cancer. J Cell Physiol. 2020;235(4):3329–39.PubMedCrossRef
36.
Kanda A, Ebihara S, Takahashi H, Sasaki H. Loxoprofen sodium suppresses mouse tumor growth by inhibiting vascular endothelial growth factor. Acta Oncol. 2003;42(1):62–70.PubMedCrossRef
37.
O’Flaherty JD, Gray S, Richard D, Fennell D, O’Leary JJ, Blackhall FH, et al. Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer. 2012;76(1):19–25.PubMedCrossRef
38.
Bayarri-Lara C, Ortega FG, de CuetoLadrónGuevara A, Puche JL, Ruiz Zafra J, de Miguel-Pérez D, et al. Circulating tumor cells identify early recurrence in patients with non-small cell lung cancer undergoing radical resection. PLoS One. 2016;11(2):e0148659.PubMedPubMedCentralCrossRef
39.
Grillet F, Bayet E, Villeronce O, Zappia L, Lagerqvist EL, Lunke S, et al. Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture. Gut. 2017;66(10):1802–10.PubMedCrossRef
40.
Watanabe T, Okumura T, Hirano K, Yamaguchi T, Sekine S, Nagata T, et al. Circulating tumor cells expressing cancer stem cell marker CD44 as a diagnostic biomarker in patients with gastric cancer. Oncol Lett. 2017;13(1):281–8.PubMedCrossRef
41.
Obermayr E, Koppensteiner N, Heinzl N, Schuster E, Holzer B, Fabikan H, et al. Cancer stem cell-like circulating tumor cells are prognostic in non-small cell lung cancer. J Pers Med. 2021;11(11):1225.PubMedPubMedCentralCrossRef
42.
Pantazaka E, Vardas V, Roumeliotou A, Kakavogiannis S, Kallergi G. Clinical relevance of mesenchymal- and stem-associated phenotypes in circulating tumor cells isolated from lung cancer patients. Cancers. 2021;13(9):2158.PubMedPubMedCentralCrossRef
43.
Makena MR, Ranjan A, Thirumala V, Reddy AP. Cancer stem cells: road to therapeutic resistance and strategies to overcome resistance. Biochim Biophys Acta Mol Basis Dis. 2020;1866(4):165339.PubMedCrossRef
44.
Chen SY, Huang YC, Liu SP, Tsai FJ, Shyu WC, Lin SZ. An overview of concepts for cancer stem cells. Cell Transplant. 2011;20(1):113–20.PubMedCrossRef
45.
Clara JA, Monge C, Yang Y, Takebe N. Targeting signalling pathways and the immune microenvironment of cancer stem cells-a clinical update. Nat Rev Clin Oncol. 2020;17(4):204–32.PubMedCrossRef
46.
Dong J, Zhu D, Tang X, Qiu X, Lu D, Li B, et al. Detection of circulating tumor cell molecular subtype in pulmonary vein predicting prognosis of stage I-III non-small cell lung cancer patients. Front Oncol. 2019;9:1139.PubMedPubMedCentralCrossRef
47.
Yang L, Lv Z, Xia W, Zhang W, Xin Y, Yuan H, et al. The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study. Clin Transl Oncol. 2018;20(7):912–21.PubMedCrossRef
48.
Zou Z, Zheng W, Fan H, Deng G, Lu SH, Jiang W, et al. Aspirin enhances the therapeutic efficacy of cisplatin in oesophageal squamous cell carcinoma by inhibition of putative cancer stem cells. Br J Cancer. 2021;125(6):826–38.PubMedPubMedCentralCrossRef
49.
Chen J, Xu R, Xia J, Huang J, Su B, Wang S. Aspirin inhibits hypoxia-mediated lung cancer cell stemness and exosome function. Pathol Res Prac. 2019;215(6):152379.CrossRef
50.
51.
Liu Y, Gao Y, Lin T. Expression of interleukin-1 (IL-1), IL-6, and tumor necrosis factor-α (TNF-α) in non-small cell lung cancer and its relationship with the occurrence and prognosis of cancer pain. Ann Palliat Med. 2021;10(12):12759–66.PubMedCrossRef
52.
Jawa RS, Anillo S, Huntoon K, Baumann H, Kulaylat M. Interleukin-6 in surgery, trauma, and critical care part II: clinical implications. J Intensive Care Med. 2011;26(2):73–87.PubMedPubMedCentralCrossRef
53.
Chang KT, Tsai CM, Chiou YC, Chiu CH, Jeng KS, Huang CY. IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol. 2005;289(3):L446–453.PubMedCrossRef
54.
Kim SM, Kwon OJ, Hong YK, Kim JH, Solca F, Ha SJ, et al. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther. 2012;11(10):2254–64.PubMedCrossRef
55.
Duan S, Tsai Y, Keng P, Chen Y, Lee SO. IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules. Oncotarget. 2015;6(29):27651–60.PubMedPubMedCentralCrossRef
56.
Shang GS, Liu L, Qin YW. IL-6 and TNF-α promote metastasis of lung cancer by inducing epithelial-mesenchymal transition. Oncol Lett. 2017;13(6):4657–60.PubMedPubMedCentralCrossRef
57.
Liu CC, Lin JH, Hsu TW, Su K, Li AF, Hsu HS, et al. IL-6 enriched lung cancer stem-like cell population by inhibition of cell cycle regulators via DNMT1 upregulation. Int J Cancer. 2015;136(3):547–59.PubMedCrossRef
58.
Brighenti E, Giannone FA, Fornari F, Onofrillo C, Govoni M, Montanaro L, et al. Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate. Oncotarget. 2016;7(39):63226–41.PubMedPubMedCentralCrossRef
59.
Tian Y, Ye Y, Gao W, Chen H, Song T, Wang D, et al. Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway. Int J Colorectal Dis. 2011;26(1):13–22.PubMedCrossRef
60.
Kim SR, Bae MK, Kim JY, Wee HJ, Yoo MA, Bae SK. Aspirin induces apoptosis through the blockade of IL-6-STAT3 signaling pathway in human glioblastoma A172 cells. Biochem Biophys Res Commun. 2009;387(2):342–7.PubMedCrossRef
61.
Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 2017;376(22):2109–21.PubMedCrossRef
62.
Mc Menamin ÚC, Cardwell CR, Hughes CM, Murray LM. Low-dose aspirin and survival from lung cancer: a population-based cohort study. BMC Cancer. 2015;15:911.PubMedPubMedCentralCrossRef
63.
Qian Y, Dai H, Li H. Low-doses of aspirin promote the growth of human PC-9 lung cancer cells through activation of the MAPK family. Exp Ther Med. 2021;22(6):1440.PubMedPubMedCentralCrossRef
64.
Bjarnason I, Scarpignato C, Holmgren E, Olszewski M, Rainsford KD, Lanas A. Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs. Gastroenterology. 2018;154(3):500–14.PubMedCrossRef
Metadata
Title
The use of non-steroid anti-inflammatory drugs during radical resection correlated with the outcome in non-small cell lung cancer
Authors
Renzhong Cai
Xuqiang Liao
Gao Li
Jia Xiang
Qianwen Ye
Minbiao Chen
Shouhan Feng
Publication date
01-12-2023
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2023
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-023-03247-8

Other articles of this Issue 1/2023

World Journal of Surgical Oncology 1/2023 Go to the issue

Research

Risk factors for cough after pulmonary resection

Research

Re-stratification of patients with copy-number low endometrial cancer by clinicopathological characteristics

Research

Impact of endoscopic metallic stent placement and emergency surgery on detection of viable circulating tumor cells for acute malignant left-sided colonic obstruction

Research

Diagnostic value of the combination of DAPK methylation in urinary sediment and B ultrasound for recurrent urinary bladder cancer

Research

Improvement of sleep quality in isolated metastatic patients with spinal cord compression after surgery

Research

Perioperative outcomes of robotic and laparoscopic surgery for colorectal cancer: a propensity score-matched analysis